Most notably, CD19 targeted CAR T cell therapy has revolutionized the treatment of B cell malignancies (leukemias and lymphomas) achieving complete remissions in up to 80% of patients with previously treated, advanced relapsed or refractory B cell acute lymphoblastic leukemia [2–4]. The gene discussed is CD19; the disease is lymphoma.